ED
GTHX

Exane Derivatives’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Exane Derivatives’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,087
Closed -$122K – 1098
2021
Q3 		$122K Buy
9,087
+2,346
+35% +$38.2K 0.03% 498
2021
Q2 		$130K Buy
6,741
+631
+10% +$14K 0.03% 512
2021
Q1 		$147K Sell
6,110
-40
-0.7% -$930 0.04% 342
2020
Q4 		$111K Buy
6,150
+320
+5% +$4.78K 0.03% 384
2020
Q3 		$67.3K Buy
5,830
+63
+1% +$1.04K 0.02% 352
2020
Q2 		$140K Buy
5,767
+29
+0.5% +$480 0.04% 244
2020
Q1 		$63.2K Buy
+5,738
New +$107K 0.02% 336

Other funds holding GTHX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Exane Derivatives's GTHX Position: Q4 2021 in Review

Exane Derivatives sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2021, closing a stake of 9,087 shares — an estimated $122K sold.

Exane Derivatives first reported a position in GTHX in Q1 2020 and held it in 7 quarters. The position peaked at $147K in Q1 2021. 108 funds tracked by Wall St. Rank hold GTHX as of Q4 2021.

  • Exane Derivatives reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Exane Derivatives sold 9,087 G1 Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $122K.
  • Exane Derivatives first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
  • Exane Derivatives's G1 Therapeutics, Inc. Common Stock position peaked at $147K in Q1 2021.
  • 108 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.